Complete response of leptomeningeal carcinomatosis secondary to breast cancer
Idriss Troussier,
Charles Canova,
Guillaume Klausner
Affiliations
Idriss Troussier
Radiation Oncology Department, Hospital Universitary of Geneva, Avenue de La Roseraie 53, 1205, Genève, Suisse, Switzerland; Radiation Oncology Department, Centre de Haute Energie, 10 Boulevard Pasteur, 06000, Nice, France
Charles Canova
Radiation Oncology Department, Centre de Haute Energie, 10 Boulevard Pasteur, 06000, Nice, France
Guillaume Klausner
University Pierre and Marie Curie, Paris Sorbonne University, 91-105 Boulevard de L’Hôpital, 75013, Paris, France; Corresponding author. Université Pierre et Marie Curie, Paris Sorbonne University, 47-83 Boulevard de l’Hôpital, 75013, Paris, France.
Leptomeningeal carcinomatosis (LC) is an unmet medical need associated with death in 4–6 weeks without treatment, delayed by 4 months in some patients with favorable prognosis and aggressive multimodal therapy. Unfortunately, most clinical trials excluded patients with LC, and the best management remains unknown.Here we present the first report of a LC secondary to HR positive breast cancer with a complete response to CDK4/6 inhibitors abemaciclib, letrozole and hippocampal-avoidance whole-brain radiotherapy.
